A FAILED pancreatic cancer treatment could be resurrected as a personalised medicine aimed at one in five patients with the disease, research suggests.
Previous trials showed that the drug rapamycin was ineffective as a general therapy for pancreatic cancer.
But new evidence suggests it might work against a particular type of tumour caused by a fault in the PTEN gene, which influences cell growth.
When rapamycin was given to mice with PTEN-defective pancreatic tumours it stopped cancer cells from spreading. In some cases, the drug also caused tumours to shrink.
An analysis of human pancreatic tumour samples found that around one in five had the defective gene, suggesting that rapamycin might help a substantial number of patients.
Lead researcher Dr Jennifer Morton, from the Cancer Research UK Beatson Institute at the University of Glasgow, said: "This is incredibly important research showing for the first time that there's potential to tailor treatment to pancreatic cancer patients based on differences in their tumour's genetic fingerprint.
"Although it's at a very early stage, it's the first time we've been able to pinpoint a genetic fault in pancreatic cancers and match it up with a specific drug.
"It's a crucial step forward in developing new treatments for this devastating disease."
The new research is published in the journal Gut.
Dr Kat Arney, science communications manager at Cancer Research UK, said: "This is a promising step towards being able to personalise treatments to them."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article